Diabetic Retinopathy Market

Diabetic Retinopathy Market is valued at USD 6647.2 Million in 2021 and expected to reach USD 10329.7 Million by 2028 with the CAGR of 6.5% over the forecast period. 

Global Diabetic Retinopathy Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2022-2028- Increasing prevalence of diabetes, rising number of product launches and approvals of new diabetic retinopathy drugs, and growing geriatric population are some of the major factors driving the growth of the Global Diabetic Retinopathy Market. 

Scope of Global Diabetic Retinopathy Market Report- 

Diabetic retinopathy (DR) is caused by damage to blood vessels in the tissue at the back of the eye. Poorly controlled blood sugar is a risk factor. There are two types of diabetic retinopathy such as non-proliferative, and proliferative. Early symptoms include floaters, dark areas of vision, blurriness, and difficulty perceiving colors. Blindness may occur. Diabetic retinopathy has a significant economic impact on health care systems and directly affects patients' quality of life. Diabetic retinopathy is the most common cause of legal blindness in people between the ages of 20 and 74. 

The Covid-19 pandemic has negatively impacted the growth of the global diabetic retinopathy market. Ophthalmology outpatient visits declined dramatically during the pandemic. DR screening was repeatedly postponed during the pandemic, especially in areas with high Covid-19 community transmission, a factor that negatively impacted the global diabetic retinopathy market. However, as global conditions have improved, the market is expected to revive soon. 

The global diabetic retinopathy market is segmented on the type, management, and region & country level. Based on type, the global diabetic retinopathy market is classified into non-proliferative, and proliferative. Based on  management, the global diabetic retinopathy market is classified into vitrectomy, laser surgery, anti-VEGF, and intraocular steroid injection.  

The regions covered in the global diabetic retinopathy market report are North America, Europe, Asia-Pacific, Latin America, and the rest of the World. Based on country level, the market of global diabetic retinopathy is sub divided into U.S., Mexico, Canada, U.K., France, Germany, China, Italy, India, Japan, Southeast Asia, Middle East Asia (Saudi Arabia, UAE, Egypt) GCC, Africa, etc. 

Key Players of Global Diabetic Retinopathy Market Report- 

Bayer AG, Ampio Pharmaceuticals, Allergan plc, Oxurion NV, Novartis AG, Sirnaomics Inc., Alimera Sciences, Genentech, BCN Peptides, Kowa Company Ltd.,  RemeGen, Aerpio Therapeutics, Hoffman-La-Roche, Regenxbio Inc., Apexian Pharmaceuticals, Inc., Ocuphire Pharma, Inc., Adverum Biotechnologies, MingSight Relin Pharmaceuticals , NovaGo Therapeutics, RIBOMIC, Retinset SL, PYC Therapeutics, PharmAbcine, Palatin Technologies, LUYE PHARMA, BONAC corporation, AptaBio Therapeutics, Ascentage Pharma, EyeGene, Applied Therapeutics, Foresee Pharmaceuticals, Everglades Biopharma, Novelty Nobility Inc, Noveome Biotherapeutics, Shanghai Henlius Biotech, EyePoint Pharmaceuticals and several others.

Report Analysis	Details
Historical data	2018 - 2021
Forecast Period	2022 - 2028
Market Size in 2021:	USD 6647.2 Million
Base year considered	2021
Forecast Period CAGR %:	6.5%
Market Size Expected in 2028:	USD 10329.7 Million
Tables, Charts & Figures:	175
Pages	200
Diabetic Retinopathy Companies	Bayer AG, Ampio Pharmaceuticals, Allergan plc, Oxurion NV, Novartis AG, Sirnaomics Inc., Alimera Sciences, Genentech, BCN Peptides, Kowa Company Ltd.,  RemeGen, Aerpio Therapeutics, Hoffman-La-Roche, Regenxbio Inc., Apexian Pharmaceuticals, Inc., Ocuphire Pharma, Inc., Adverum Biotechnologies, MingSight Relin Pharmaceuticals , NovaGo Therapeutics, RIBOMIC, Retinset SL, PYC Therapeutics, PharmAbcine, Palatin Technologies, LUYE PHARMA, BONAC corporation, AptaBio Therapeutics, Ascentage Pharma, EyeGene, Applied Therapeutics, Foresee Pharmaceuticals, Everglades Biopharma, Novelty Nobility Inc, Noveome Biotherapeutics, Shanghai Henlius Biotech, EyePoint Pharmaceuticals and several others.
Segments Covered	By Type, By Management
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

 

News- 

OcuTerra Therapeutics Announced First Patient Dosed in OTT166 Phase 2 DR: EAM Clinical Trial for Diabetic Retinopathy (DR) 

On August 2nd, 2022; OcuTerra Therapeutics, Inc., a clinical-stage ophthalmology company developing innovative drugs to treat eye diseases for which the current """"""""watch-and-wait"""""""" standard of care does not prevent or control disease progression, announced the first patient with his Phase 2 DR: EAM diabetic retinopathy: (early active management) has revealed dosing.  

FDA Approved Aflibercept sBLA for the Treatment of Diabetic Retinopathy 

On July 3rd, 2022; The FDA accepted aflibercept's (Eylea; Regeneron Pharmaceuticals) Supplemental Biologics License Application (sBLA) for a 2 mg every 16-week dosing regimen for individuals with diabetic retinopathy (DR) after an initial monthly dose. 

FDA Approved Eylea (Aflibercept) Injection for Diabetic Retinopathy 

On May 13th, 2019; Regeneron Pharmaceuticals, Inc. announced that the U.S. The Food and Drug Administration (FDA) has approved EYLEA (aflibercept) injection to treat all stages of diabetic retinopathy (DR) and reduce the risk of blindness. 

Google Launched India Program to Screen Diabetics for Eye Conditions that Can Cause Blindness 

On February 25th, 2019; Google and Verily developed technology to diagnose diabetic retinopathy and diabetic macular edema. These conditions can cause severe vision loss but can be prevented if caught early. There is a massive shortage of ophthalmologists to screen the diabetic population, especially in India. 

Increasing Prevalence of Diabetes, Rising Number of Product Launches and Approvals of New Diabetic Retinopathy Drugs, and Growing Geriatric Population are Some of the Major Factors Driving the Market Growth  

One of the major factors driving the growth of the diabetic retinopathy market is the increasing prevalence of diabetes. The increasing prevalence of diabetes is the primary driver for the growth of the diabetic retinopathy market. Along with this, increasing cases of blindness due to diabetes will further influence the market dynamics during the forecast period. For example; according to the international diabetes foundation, in 2021; 537 million adults (20-79 years) are living with diabetes 1 in 10. By 2045 this number is projected to increase to 643 million by 2030 & 783 million.  In addition, the rising number of product launches and approvals of new diabetic retinopathy drugs are also boosting the growth of the diabetic retinopathy market. For instance; on May 13th, 2019; Regeneron Pharmaceuticals, Inc. announced that the U.S. The Food and Drug Administration (FDA) has approved EYLEA (aflibercept) injection to treat all stages of diabetic retinopathy (DR) and reduce the risk of blindness. 

Moreover, the growing geriatric population is also supplementing the diabetic retinopathy market growth. This population is more prone to these kind of diseases. For instance; in 2007 the number of patients over 65 with diabetic retinopathy in the United States was about 2.5 million. It is expected to almost quadruple to 9.9 million by the year 2050. In addition to this diabetic retinopathy is increasingly causing vision loss in the elderly. In adults aged 50 and older, vision impairment due to DR increased by 9.6%.  

However, complications and adverse reactions associated with diabetic retinopathy may hinder the growth of the global diabetic retinopathy market. Despite that, the increasing advancements in this field may create more opportunities for the further growth of the market. 

North America Holds a Major Share in the Global Diabetic Retinopathy Market

Geographically, North America is expected to capture a significant share in the global diabetic retinopathy market within the forecast period due to the increasing prevalence of diabetes, rising technological advancement, and favorable government initiatives related to drug development in this region. The growing prevalence of diabetes is driving the growth of the market. For instance; according to the Central for Disease Control & Prevention, on January 18th, 2022; 37.3 million people have diabetes (11.3% of the United States population). In addition, the rising number of technological advancements is another factor supplementing the market growth in this region. For instance; as per the news published, on March 21st, 2018; FDA approved Genentech’s Lucentis (Ranibizumab Injection) 0.3 mg prefilled syringe for diabetic macular edema and diabetic retinopathy. 

Europe is the fastest-growing region in the global diabetic retinopathy market due to the increasing prevalence of diabetes, rising awareness regarding diabetes, and high disposable incomes. For instance; according to Europe World Health Organization, in 2022 about 60 million people with diabetes in Europe. 

Global Diabetic Retinopathy Market Segmentation: 

By Type

• Non-proliferative 
• Proliferative  

By Management

• Vitrectomy 
• Laser Surgery 
• Anti VEGF 
• Intraocular Steroid Injection  

Diabetic Retinopathy Market Key Players:

• Bayer AG
• Ampio Pharmaceuticals
• Allergan plc
• Oxurion NV
• Novartis AG
• Sirnaomics Inc
• Alimera Sciences
• Genentech
• BCN Peptides
• Kowa Company Ltd
• RemeGen
• Aerpio Therapeutics
• Hoffman-La-Roche
• Regenxbio Inc
• Apexian Pharmaceuticals Inc
• Ocuphire Pharma, Inc
• Adverum Biotechnologies
• MingSight Relin Pharmaceuticals
• NovaGo Therapeutics
• RIBOMIC
• Retinset SL
• PYC Therapeutics
• PharmAbcine
• Palatin Technologies
• LUYE PHARMA
• BONAC corporation
• AptaBio Therapeutics
• Ascentage Pharma
• EyeGene
• Applied Therapeutics
• Foresee Pharmaceuticals
• Everglades Biopharma
• Novelty Nobility Inc
• Noveome Biotherapeutics
• Shanghai Henlius Biotech
• EyePoint Pharmaceuticals
• others

Regional Analysis

North America

• U.S.
• Canada

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Switzerland
• Belgium
• Rest of Europe

Asia-Pacific

• South Korea
• Japan
• China
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Colombia
• Brazil
• Argentina
• Peru
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Key Benefits of Global Diabetic Retinopathy Market Report– 

• Global Diabetic Retinopathy Market report covers in-depth historical and forecast analysis 
• Global Diabetic Retinopathy Market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market Opportunities, Competitive Analysis, Regional and Country Level. 
• Global Diabetic Retinopathy Market report helps to identify opportunities in marketplace.    
• Global Diabetic Retinopathy Market report covers extensive analysis of emerging trends and competitive landscape.